<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Cardiovascular Toxicology</journal-title></journal-title-group><issn pub-type="ppub">1530-7905</issn><issn pub-type="epub">1559-0259</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10998799</article-id><article-id pub-id-type="pmcid-ver">PMC10998799.1</article-id><article-id pub-id-type="pmcaid">10998799</article-id><article-id pub-id-type="pmcaiid">10998799</article-id><article-id pub-id-type="pmid">38499940</article-id><article-id pub-id-type="doi">10.1007/s12012-024-09843-8</article-id><article-id pub-id-type="publisher-id">9843</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients with Atrial Fibrillation and Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8654-5444</contrib-id><name name-style="western"><surname>Truong</surname><given-names initials="B">Bang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="J">Jingyi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hornsby</surname><given-names initials="L">Lori</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fox</surname><given-names initials="B">Brent</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chou</surname><given-names initials="C">Chiahung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4624-9963</contrib-id><name name-style="western"><surname>Qian</surname><given-names initials="J">Jingjing</given-names></name><address><email>jzq0004@auburn.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02v80fc35</institution-id><institution-id institution-id-type="GRID">grid.252546.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 8753</institution-id><institution>Department of Health Outcomes Research and Policy, </institution><institution>Auburn University Harrison College of Pharmacy, </institution></institution-wrap>4306d Walker Building, Auburn, AL 36849 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02v80fc35</institution-id><institution-id institution-id-type="GRID">grid.252546.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 8753</institution-id><institution>Department of Mathematics and Statistics, </institution><institution>Auburn University College of Sciences and Mathematics, </institution></institution-wrap>Auburn, AL USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02v80fc35</institution-id><institution-id institution-id-type="GRID">grid.252546.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 8753</institution-id><institution>Department of Pharmacy Practice, </institution><institution>Auburn University Harrison College of Pharmacy, </institution></institution-wrap>Auburn, AL USA </aff></contrib-group><author-notes><fn fn-type="com"><p>Handling Editor: Vittorio Fineschi.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>24</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">459550</issue-id><fpage>365</fpage><lpage>374</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>08</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-08 00:25:13.483"><day>08</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12012_2024_Article_9843.pdf"/><abstract id="Abs1"><p id="Par1">In this study, we leveraged machine learning&#160;(ML) approach to develop and validate new assessment tools for predicting&#160;stroke and bleeding among patients with atrial fibrillation (AFib) and cancer. We conducted a retrospective cohort study including patients who were newly diagnosed with AFib with a record of cancer from the 2012&#8211;2018 Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The ML algorithms were developed and validated separately for each outcome by fitting elastic net, random forest (RF), extreme gradient boosting (XGBoost), support vector machine (SVM), and neural network models with tenfold cross-validation (train:test&#8201;=&#8201;7:3). We obtained area under the curve (AUC), sensitivity, specificity, and F2 score as performance metrics. Model calibration was assessed using Brier score. In sensitivity analysis, we resampled data using Synthetic Minority Oversampling Technique (SMOTE). Among 18,388 patients with AFib and cancer, 523 (2.84%) had ischemic stroke and 221 (1.20%) had major bleeding within one year after AFib diagnosis. In prediction of ischemic stroke, RF significantly outperformed other ML models [AUC (0.916, 95% CI 0.887&#8211;0.945), sensitivity 0.868, specificity 0.801, F2 score 0.375, Brier score&#8201;=&#8201;0.035]. However, the performance of ML algorithms in prediction of major bleeding was low with highest AUC achieved by RF (0.623, 95% CI 0.554&#8211;0.692). RF models performed better than CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores. SMOTE did not improve the performance of the ML algorithms. Our study demonstrated a promising application of ML in stroke prediction among patients with AFib and cancer. This tool may be leveraged in assisting clinicians to identify patients at high risk of stroke and optimize treatment decisions.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12012-024-09843-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>AFib</kwd><kwd>Cancer</kwd><kwd>Stroke</kwd><kwd>Bleeding</kwd><kwd>Prediction</kwd><kwd>Machine learning</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">In the United States (US), atrial fibrillation (AFib) is projected to affect 12 million people by 2030 [<xref ref-type="bibr" rid="CR1">1</xref>]. AFib has been recorded as the primary diagnosis for more than 454,000 hospitalizations and contributed to more than 158,000 deaths annually [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. The coexistence of cancer among patients with AFib increases incidence of adverse events such as ischemic stroke, venous thromboembolism (VTE), bleeding, and death compared with AFib patients without cancer [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. Current management of patients with AFib and cancer with oral anticoagulants (OACs) remains suboptimal due to insufficient evidence regarding risk assessment and treatment optimization from clinical practice guidelines [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par3">CHA<sub>2</sub>DS<sub>2</sub>-VASc score, a composite score of congestive heart failure (1 point), hypertension (1), age&#8201;&#8805;&#8201;75 (2), diabetes mellitus (1), prior stroke, TIA, or thromboembolism (2), vascular disease (e.g. peripheral artery disease, myocardial infarction, aortic plaque) (1), age 65&#8211;74&#160;years, and sex category (1), has been used to evaluate of risk of stroke in patients with AFib [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The clinical guidelines recommend OACs for patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores&#8201;&#8805;&#8201;2 [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. However, CHA<sub>2</sub>DS<sub>2</sub>-VASc score is not highly predictive in patients with AFib and cancer [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. HAS-BLED score has been widely used for risk of bleeding stratification. The HAS-BLED is calculated by the presence of hypertension (1), abnormal renal/liver function (1&#8201;+&#8201;1), stroke (1), bleeding tendency or predisposition (1), labile INR for patients taking warfarin (1), age&#8201;&#8805;&#8201;65, drugs (concomitant aspirin or NSAIDs) or excess alcohol use (1&#8201;+&#8201;1) [<xref ref-type="bibr" rid="CR15">15</xref>]. The 2020 European Society of Cardiology (ESC) guideline suggests a score of&#8201;&#8805;&#8201;3 indicates &#8220;high risk&#8221; [<xref ref-type="bibr" rid="CR12">12</xref>]. However, it is not recommend against the use of anticoagulants, but caution and regular monitoring after treatment initiation are needed [<xref ref-type="bibr" rid="CR12">12</xref>]. Nonetheless, the usefulness of HAS-BLED in cancer patients are inconclusive because cancer is an independent risk factor of bleeding among patients with AFib [<xref ref-type="bibr" rid="CR16">16</xref>]. Pastori et al. compared the performances of multiple bleeding risk scores among cancer patients and found that HAS-BLED was not highly predictive of major and gastrointestinal bleeding [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par4">Therefore, it is an urgent need to develop new risk assessment tools for stroke and bleeding in patients with AFib and cancer. Traditional risk assessment tools such as CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED are simple and easy for implementation among clinicians because they are linear combinations of patients&#8217; diseases and conditions. However, when the relationships between patients&#8217; characteristics and outcomes become more complicated, these tools may not perform well in patients with AFib and cancer. Recently, machine learning (ML) algorithms have been increasingly used to support clinical decision-making such as or identifying patients with dementia in primary care, anticoagulation monitoring, and measuring pretreatment quality of care before treatment in patients with hepatitis C [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. Compared with conventional regression-based methods, ML models are able to learn from the data when the association between predictors and outcome variables is not linear. ML models have overperformed parametric regressions in handling high-dimensional data and interactions between variables in a complex data structure [<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par5">In this study, we developed and validated ML algorithms to predict risk of stroke and bleeding events among patients with AFib and cancer, using US cancer registry and administrative claims linked datasets.</p></sec><sec id="Sec2"><title>Materials and Methods</title><sec id="Sec3"><title>Study Design and Data Source</title><p id="Par6">We followed the Transparent Reporting of a multivariable prediction model for individual Prognosis Or Diagnosis (TRIPOD) guideline to develop and validate ML algorithms to separately predict risk of stroke and risk of bleeding in patients with AFib and cancer [<xref ref-type="bibr" rid="CR23">23</xref>]. We conducted a retrospective cohort study using the 2011&#8211;2019 Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare database. SEER registry contains demographics, cancer characteristics, treatment, and follow-up of cancer patients across the US, [<xref ref-type="bibr" rid="CR24">24</xref>] while Medicare data capture health care services utilization (medical claims, procedures, and prescriptions) of beneficiaries [<xref ref-type="bibr" rid="CR25">25</xref>]. The study design and approach are illustrated in Figures S1, S2.</p></sec><sec id="Sec4"><title>Participants</title><p id="Par7">We included individuals aged&#8201;&#8805;&#8201;66, newly diagnosed non-valvular atrial fibrillation (NVAF) from 1/1/2012 to 12/31/2018. AFib was defined as any International Classification of Disease-9th Revision-Clinical Modification (ICD-9-CM) codes 427.31 or 427.32 or any International Classification of Disease-10th Revision-Clinical Modification (ICD-10-CM) codes I48.xx in any position on one Medicare inpatient claim or on two outpatient claims at least 7&#160;days but&#8201;&lt;&#8201;1&#160;year apart [<xref ref-type="bibr" rid="CR26">26</xref>]. We removed patients with valvular diseases, repair or replacement, venous thromboembolism, or joint replacement during the 12&#160;months baseline period because OACs are also indicated for these conditions and their clinical management are different from AFib [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Eligible records were then linked to SEER files to identify patients with breast, lung, or prostate cancer&#8212;the most common cancer types with AFib&#8212;from at any time before the initial AFib diagnosis (ICD-O-3 codes C50.0&#8211;C50.9 for breast; C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, C33.9 for lung; C61.9 for prostate cancer). Patients were required to continuously enroll in Medicare part A, B, D, and without Medicare Advantage or Health Maintenance Organization (HMO) for at least 12&#160;months before and 12&#160;months after NVAF diagnosis. Since OAC initiation during follow-up may modify the risk of stroke and bleeding, we excluded patients who initiated warfarin or direct anticoagulants (DOACs) within 12&#160;months before or after NVAF diagnosis. All ICD codes to identify these conditions can be found in Table <xref rid="MOESM1" ref-type="media">S1</xref>, Supplementary materials.</p></sec><sec id="Sec5"><title>Outcomes</title><p id="Par8">The outcomes of interest were ischemic stroke and major bleeding events identified within 12&#160;months after AFib diagnosis. We defined major bleeding and ischemic stroke using validated algorithms defined by ICD-9-CM and ICD-10-CM codes in the primary diagnosis from Medicare medical claims files [<xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec6"><title>Predictors</title><p id="Par9">We selected potential predictors from literature review and based on availability in SEER-Medicare data [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The following predictors were included: <italic toggle="yes">demographics</italic> (index age, sex, race/ethnicity, calendar year, geographical region, urbanicity), <italic toggle="yes">socioeconomic factors</italic> (household median income, percentage of household with education level below high school, and Medicaid eligibility), <italic toggle="yes">comorbidities</italic> (hypertension, congestive heart failure, diabetes, prior stroke, vascular diseases, prior bleeding, renal diseases, liver diseases, alcohol use disorders, asthma/chronic obstructive pulmonary disease, hematological disorders, dementia, depression, thrombocytopenia, acute kidney disease, peptic ulcer disease), <italic toggle="yes">cancer characteristics</italic> (time from cancer diagnosis to the onset of AFib, cancer type, cancer stage, tumor grade, active cancer status [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]), <italic toggle="yes">cancer treatment</italic> (radiation, and cancer-directed surgery, and potentially interacting antineoplastic agents), and <italic toggle="yes">medication history</italic> (antiplatelet/non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), calcium channel blockers, beta blockers, antiarrhythmic medications, diuretics, statin, pump proton inhibitors, and serotonin reuptake inhibitors). Features were obtained during 12&#160;months before the index date. All diagnosis codes and procedure codes for covariate ascertainment are described in Table <xref rid="MOESM1" ref-type="media">S1</xref>, Supplementary materials.</p></sec><sec id="Sec7"><title>Algorithms, Model Training and Validation</title><p id="Par10">Descriptive statistics was used to compare the characteristics of the full cohort and between patients with and without the outcomes. MissForest was used to impute missing values for predictors [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The original dataset was then randomly split into two datasets: training (70%) and testing datasets (30%) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], with similar distribution of the outcomes in both datasets. In the algorithm training process, ML models (elastic net logistic regression, random forest (RF), support vector machine (SVM), extreme gradient boosting (XGBoost), and neural network) were fitted with ten-fold cross-validation (CV) [<xref ref-type="bibr" rid="CR38">38</xref>]. The fitted models were then tested on the rest of the data. Since stroke and bleeding occurred in less than 10% within one year among AFib patients [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], our classification is severely imbalanced due to the prediction of minority class (stroke and bleeding) [<xref ref-type="bibr" rid="CR40">40</xref>]. Therefore, we shifted the decision threshold to the true event probability rather than using the default threshold of 0.50 [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. The description of the models can be found in Technical Appendix.</p></sec><sec id="Sec8"><title>Model Performance, Calibration, and Evaluation</title><p id="Par11">To assess algorithm discrimination, we calculated the area under the receiver operating characteristic curve (AUROC or AUC) as the main metrics and compared the AUC across algorithms using DeLong&#8217;s test [<xref ref-type="bibr" rid="CR42">42</xref>]. Other performance metrics were also extracted, including sensitivity, specificity, and F2 score. Since true positive (patients actually having stroke/bleeding) is more important and false negative cases (patients at high risk of the event were not identified) are more costly, we selected F2 score over F1 score [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. In addition, we generated feature importance plots to identify the contribution of each variable in predicting the outcomes [<xref ref-type="bibr" rid="CR44">44</xref>]. Since feature importance using Gini index in tree-based algorithms (i.e., RF and XGBoost) are subject to bias [<xref ref-type="bibr" rid="CR45">45</xref>], we computed out-of-bag impurity reduction feature importance as an alternative [<xref ref-type="bibr" rid="CR46">46</xref>]. Model calibration was performed to compare the true probability of the outcome versus a model&#8217;s prediction with Brier score [<xref ref-type="bibr" rid="CR47">47</xref>]. We also compared the performances of ML algorithms with CHA<sub>2</sub>DS<sub>2</sub>-VASc score or HAS-BLED score in predicting ischemic stroke and major bleeding, respectively. In predicting ischemic stroke, we fitted logistic regressions with CHA<sub>2</sub>DS<sub>2</sub>-VASc score as the predictor using the training data and validated the model on the testing data. Likewise, we predicted the risk of major bleeding on HAS-BLED score. Sensitivity, specificity, and AUC were obtained for these models. ML algorithms were developed using RStudio (version 3.6.2; Boston, MA, USA) and data analysis was conducted using SAS (version 9.4, SAS Institute, Inc., Cary, NC, USA).</p></sec><sec id="Sec9"><title>Sensitivity Analyses</title><p id="Par12">Since our classification problem was severely imbalanced, we used Synthetic Minority Oversampling Technique (SMOTE) to account for imbalance distribution of the outcome variables [<xref ref-type="bibr" rid="CR48">48</xref>]. Model development and validation were conducted on the resampling dataset.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Study Sample and Characteristics</title><p id="Par13">The final cohort consisted of 18,388 patients, of whom 523 (2.84%) had ischemic stroke and 221 (1.20%) had major bleeding within one year after AFib diagnosis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The characteristics of study sample are described in Table S2. Overall, the mean (standard deviation) age was 76.59 (7.13), 8483 (46.13%) were women, and the majority were White (85.11%) and residing in the Northeast (39.13%), or West (34.40%) region. The median (interquartile range) duration from cancer diagnosis to AFib onset was 17 (2&#8211;40) months. Compared with non-stroke patients, patients who had stroke were more likely to have breast cancer [(227 (43.40%) vs. 5416 (30.32%)], use potential interaction agents [139 (26.58%) vs. 825 (21.41%)], diabetes [188 (35.95%) vs. 5433 (30.41)], history of stroke [96 (18.36) vs. 1446 (8.09)], and vascular diseases [136 (26.00) vs. 4249 (23.78)] but less likely to have lung cancer [106 (20.27%) vs 6059 (33.92%)]. Compared with non-bleeding patients, patients who had bleeding were more likely to have breast cancer [84 (38.01%) vs. 5559 (30.60%)], history stroke [53 (23.98%) vs. 1489 (8.20%)], vascular diseases [63 (28.51%) vs. 4322 (23.79%)], and history of bleeding [72 (32.58%) vs. 3771 (20.76%)] (Table S3).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flowchart diagram for study sample. <italic toggle="yes">VTE</italic> Venous thromboembolism, <italic toggle="yes">AFib</italic> Atrial Fibrillation, <italic toggle="yes">OAC</italic> Oral Anticoagulant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12012_2024_9843_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>Algorithm Performance and Comparison</title><sec id="Sec13"><title>Ischemic Stroke Prediction</title><p id="Par14">The performances of ML models in the original sample are described in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The AUCs of elastic net, RF, XGBoost, SVM, and neural network were 0.684 (95% CI 0.641&#8211;0.727), 0.916 (95% CI 0.887&#8211;0.945), 0.737 (95% CI 0.698&#8211;0.777), 0.545 (95% CI 0.502&#8211;0.588), and 0.625 (95% CI 0.579&#8211;0.672), respectively. RF outperformed other ML models in AUC (0.916, 95% CI 0.887&#8211;0.945), sensitivity (0.868), specificity (0.801), and F2 score (0.375). The best calibration was achieved in RF algorithm (Brier score&#8201;=&#8201;0.035) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Although CHA<sub>2</sub>DS<sub>2</sub>-VASc score showed a higher sensitivity (0.829) compared to other ML models (except for RF), its specificity was low (0.268). Top five important features of RF algorithm were socioeconomic factors (proportion of household with no high school education level and median household median income), time from cancer diagnosis to AFib onset, history of stroke, and concomitant use of ACE inhibitors or ARBs. History of stroke and time from cancer diagnosis to AFib onset were the most important features in all ML models (Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, S3&#8211;S6).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Model performance of machine learning models for ischemic stroke prediction</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Sensitivity</th><th align="left" colspan="1" rowspan="1">Specificity</th><th align="left" colspan="1" rowspan="1">AUROC</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value*</th><th align="left" colspan="1" rowspan="1">F2 score</th><th align="left" colspan="1" rowspan="1">Brier score</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Original data</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Elastic net</td><td char="." align="char" colspan="1" rowspan="1">0.698</td><td char="." align="char" colspan="1" rowspan="1">0.574</td><td align="left" colspan="1" rowspan="1">0.684 (0.641&#8211;0.727)</td><td align="left" colspan="1" rowspan="1">Reference</td><td char="." align="char" colspan="1" rowspan="1">0.183</td><td char="." align="char" colspan="1" rowspan="1">0.055</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;RF</td><td char="." align="char" colspan="1" rowspan="1">0.868</td><td char="." align="char" colspan="1" rowspan="1">0.801</td><td align="left" colspan="1" rowspan="1">0.916 (0.887&#8211;0.945)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">0.375</td><td char="." align="char" colspan="1" rowspan="1">0.035</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;XGBoost</td><td char="." align="char" colspan="1" rowspan="1">0.723</td><td char="." align="char" colspan="1" rowspan="1">0.608</td><td align="left" colspan="1" rowspan="1">0.737 (0.698&#8211;0.777)</td><td align="left" colspan="1" rowspan="1">0.005</td><td char="." align="char" colspan="1" rowspan="1">0.202</td><td char="." align="char" colspan="1" rowspan="1">0.054</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;SVM</td><td char="." align="char" colspan="1" rowspan="1">0.434</td><td char="." align="char" colspan="1" rowspan="1">0.589</td><td align="left" colspan="1" rowspan="1">0.545 (0.502&#8211;0.588)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">0.121</td><td char="." align="char" colspan="1" rowspan="1">0.055</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NN</td><td char="." align="char" colspan="1" rowspan="1">0.692</td><td char="." align="char" colspan="1" rowspan="1">0.511</td><td align="left" colspan="1" rowspan="1">0.625 (0.579&#8211;0.672)</td><td align="left" colspan="1" rowspan="1">0.023</td><td char="." align="char" colspan="1" rowspan="1">0.161</td><td char="." align="char" colspan="1" rowspan="1">0.056</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CHA<sub>2</sub>DS<sub>2</sub>-VASc</td><td char="." align="char" colspan="1" rowspan="1">0.829</td><td char="." align="char" colspan="1" rowspan="1">0.268</td><td align="left" colspan="1" rowspan="1">0.580 (0.534&#8211;0.623)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="7" rowspan="1">SMOTE resampling</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Elastic net</td><td char="." align="char" colspan="1" rowspan="1">0.577</td><td char="." align="char" colspan="1" rowspan="1">0.620</td><td align="left" colspan="1" rowspan="1">0.648 (0.603&#8211;0.693)</td><td align="left" colspan="1" rowspan="1">Reference</td><td char="." align="char" colspan="1" rowspan="1">0.164</td><td char="." align="char" colspan="1" rowspan="1">0.446</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;RF</td><td char="." align="char" colspan="1" rowspan="1">0.801</td><td char="." align="char" colspan="1" rowspan="1">0.334</td><td align="left" colspan="1" rowspan="1">0.633 (0.587&#8211;0.675)</td><td align="left" colspan="1" rowspan="1">0.0352</td><td char="." align="char" colspan="1" rowspan="1">0.213</td><td char="." align="char" colspan="1" rowspan="1">0.442</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;XGBoost</td><td char="." align="char" colspan="1" rowspan="1">0.667</td><td char="." align="char" colspan="1" rowspan="1">0.529</td><td align="left" colspan="1" rowspan="1">0.633 (0.588&#8211;0.678)</td><td align="left" colspan="1" rowspan="1">0.0408</td><td char="." align="char" colspan="1" rowspan="1">0.160</td><td char="." align="char" colspan="1" rowspan="1">0.440</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;SVM</td><td char="." align="char" colspan="1" rowspan="1">0.560</td><td char="." align="char" colspan="1" rowspan="1">0.633</td><td align="left" colspan="1" rowspan="1">0.650 (0.604&#8211;0.695)</td><td align="left" colspan="1" rowspan="1">0.1027</td><td char="." align="char" colspan="1" rowspan="1">0.172</td><td char="." align="char" colspan="1" rowspan="1">0.446</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NN</td><td char="." align="char" colspan="1" rowspan="1">0.372</td><td char="." align="char" colspan="1" rowspan="1">0.752</td><td align="left" colspan="1" rowspan="1">0.580 (0.534&#8211;0.626)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">0.152</td><td char="." align="char" colspan="1" rowspan="1">0.309</td></tr></tbody></table><table-wrap-foot><p>AUROC area under receiver operating characteristic curve, RF random forest, XGBoost extreme gradient boosting, SVM&#160;support vector machine, NN neural network, SMOTE&#160;synthetic minority oversampling technique</p><p>*DeLong&#8217;s test</p><p>&#8211;: not calculated</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Feature importance plot of random forest algorithm for ischemic stroke prediction (original data)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12012_2024_9843_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec14"><title>Major Bleeding Prediction</title><p id="Par15">For bleeding prediction, performances of ML models were poor (all AUCs&#8201;&lt;&#8201;0.7 in original sample) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The AUCs of elastic net, RF, XGBoost, SVM, and neural network were 0.575 (95% CI 0.503&#8211;0.649), 0.623 (95% CI 0.554&#8211;0.692), 0.578 (95% CI 0.510&#8211;0.646), 0.546 (95% CI 0.472&#8211;0.619), 0.504 (95% CI 0.432&#8211;0.575), respectively. RF outperformed other models in AUC (0.623 (95% CI 0.554&#8211;0.692). However, sensitivity was highest for SVM algorithm (0.652), and best specificity was achieved in elastic net algorithm (0.689). There was no difference in calibration of five algorithms. HAS-BLED score failed to identify patients with major bleeding (sensitivity&#8201;=&#8201;0.052). Proportion of household with no high school education level, median household median income, time from cancer diagnosis to AFib onset, history of stroke, history of bleeding were top five important features of RF algorithm. History of bleeding was among top 5 important features in elastic net, RF, XGBoost, and neural network algorithms (Figs.&#160;<xref rid="Fig3" ref-type="fig">3</xref><bold>, S7-S10</bold>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Model performance of machine learning models for major bleeding prediction</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Sensitivity</th><th align="left" colspan="1" rowspan="1">Specificity</th><th align="left" colspan="1" rowspan="1">AUC</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">F2</th><th align="left" colspan="1" rowspan="1">Brier score</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Original data</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Elastic net</td><td char="." align="char" colspan="1" rowspan="1">0.424</td><td char="." align="char" colspan="1" rowspan="1">0.689</td><td align="left" colspan="1" rowspan="1">0.575 (0.503&#8211;0.649)</td><td align="left" colspan="1" rowspan="1">Reference</td><td char="." align="char" colspan="1" rowspan="1">0.070</td><td char="." align="char" colspan="1" rowspan="1">0.023</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;RF</td><td char="." align="char" colspan="1" rowspan="1">0.515</td><td char="." align="char" colspan="1" rowspan="1">0.671</td><td align="left" colspan="1" rowspan="1">0.623 (0.554&#8211;0.692)</td><td align="left" colspan="1" rowspan="1">0.0003</td><td char="." align="char" colspan="1" rowspan="1">0.081</td><td char="." align="char" colspan="1" rowspan="1">0.024</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;XGBoost</td><td char="." align="char" colspan="1" rowspan="1">0.439</td><td char="." align="char" colspan="1" rowspan="1">0.641</td><td align="left" colspan="1" rowspan="1">0.578 (0.510&#8211;0.646)</td><td align="left" colspan="1" rowspan="1">0.7210</td><td char="." align="char" colspan="1" rowspan="1">0.064</td><td char="." align="char" colspan="1" rowspan="1">0.024</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;SVM</td><td char="." align="char" colspan="1" rowspan="1">0.652</td><td char="." align="char" colspan="1" rowspan="1">0.357</td><td align="left" colspan="1" rowspan="1">0.546 (0.472&#8211;0.619)</td><td align="left" colspan="1" rowspan="1">0.0726</td><td char="." align="char" colspan="1" rowspan="1">0.056</td><td char="." align="char" colspan="1" rowspan="1">0.024</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NN</td><td char="." align="char" colspan="1" rowspan="1">0.470</td><td char="." align="char" colspan="1" rowspan="1">0.497</td><td align="left" colspan="1" rowspan="1">0.504 (0.432&#8211;0.575)</td><td align="left" colspan="1" rowspan="1">0.0122</td><td char="." align="char" colspan="1" rowspan="1">0.051</td><td char="." align="char" colspan="1" rowspan="1">0.024</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;HAS-BLED</td><td char="." align="char" colspan="1" rowspan="1">0.052</td><td char="." align="char" colspan="1" rowspan="1">0.960</td><td align="left" colspan="1" rowspan="1">0.574 (0.506&#8211;0.637)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="7" rowspan="1">SMOTE resampling</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Elastic net</td><td char="." align="char" colspan="1" rowspan="1">0.348</td><td char="." align="char" colspan="1" rowspan="1">0.722</td><td align="left" colspan="1" rowspan="1">0.564 (0.492&#8211;0.635)</td><td align="left" colspan="1" rowspan="1">Reference</td><td char="." align="char" colspan="1" rowspan="1">0.064</td><td char="." align="char" colspan="1" rowspan="1">0.378</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;RF</td><td char="." align="char" colspan="1" rowspan="1">0.863</td><td char="." align="char" colspan="1" rowspan="1">0.182</td><td align="left" colspan="1" rowspan="1">0.551 (0.478&#8211;0.625)</td><td align="left" colspan="1" rowspan="1">0.2752</td><td char="." align="char" colspan="1" rowspan="1">0.057</td><td char="." align="char" colspan="1" rowspan="1">0.048</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;XGBoost</td><td char="." align="char" colspan="1" rowspan="1">0.515</td><td char="." align="char" colspan="1" rowspan="1">0.517</td><td align="left" colspan="1" rowspan="1">0.553 (0.477&#8211;0.630)</td><td align="left" colspan="1" rowspan="1">0.2813</td><td char="." align="char" colspan="1" rowspan="1">0.057</td><td char="." align="char" colspan="1" rowspan="1">0.050</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;SVM</td><td char="." align="char" colspan="1" rowspan="1">0.348</td><td char="." align="char" colspan="1" rowspan="1">0.714</td><td align="left" colspan="1" rowspan="1">0.562 (0.490&#8211;0.634)</td><td align="left" colspan="1" rowspan="1">0.4052</td><td char="." align="char" colspan="1" rowspan="1">0.062</td><td char="." align="char" colspan="1" rowspan="1">0.375</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NN</td><td char="." align="char" colspan="1" rowspan="1">0.136</td><td char="." align="char" colspan="1" rowspan="1">0.849</td><td align="left" colspan="1" rowspan="1">0.520 (0.449&#8211;0.590)</td><td align="left" colspan="1" rowspan="1">0.2752</td><td char="." align="char" colspan="1" rowspan="1">0.041</td><td char="." align="char" colspan="1" rowspan="1">0.200</td></tr></tbody></table><table-wrap-foot><p>AUROC area under receiver operating characteristic curve,&#160;RF random forest, XGBoost extreme gradient boosting, SVM&#160;support vector machine, NN neural network, SMOTE&#160;synthetic minority oversampling technique</p><p>*DeLong&#8217;s test</p><p>&#8211;: not calculated</p></table-wrap-foot></table-wrap><fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Feature importance plot of random forest algorithm for major bleeding prediction (original data)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12012_2024_9843_Fig3_HTML.jpg"/></fig></p></sec></sec><sec id="Sec15"><title>Sensitivity Analysis</title><p id="Par16">There was no major improvement in the performance metrics using SMOTE resampling for ischemic stroke and major bleeding prediction across five ML algorithms. SMOTE resampling worsened the calibration of the algorithms with larger Brier score compared with original sample (Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). Feature importance of ML algorithms in SMOTE samples are described in Figures S11-S15 (ischemic stroke) and Figures S16-20 (major bleeding).</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par17">Our study is among the first studies that developed and validated ML algorithms to predict adverse outcomes exclusively for patients with AFib and cancer. In this cohort study, we demonstrated that incorporating ML algorithms into SEER-Medicare data can be a promising tool to predict short-term (1&#160;year) risk of stroke among patients with AFib and cancer. Among older adults with cancer who were newly diagnosed with AFib, clinicians can collect patients&#8217; demographics, socioeconomic status, medical history, and medication history from routine medical records and/or patient survey, then leverage this tool to predict patients&#8217; risk of stroke. Our ML algorithms help clinicians identify high-risk patients and facilitate treatment decision (i.e., medication or non-pharmacological intervention) among older adults with AFib and cancer across the US.</p><p id="Par18">RF outperformed other ML models in all metrics (AUC, sensitivity, specificity, and F2 score) for ischemic stroke. Although widely accepted as a risk assessment tool for stroke among patients with AFib, CHA<sub>2</sub>DS<sub>2</sub>-VASc score failed to achieve high performance in patients with AFib and cancer, especially in new onset AFib [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. In this study, CHA<sub>2</sub>DS<sub>2</sub>-VASc score performed better than ML models, except for RF in identifying patients with ischemic stroke, however, CHA<sub>2</sub>DS<sub>2</sub>-VASc score could not differentiate those with lower risk (low specificity). In fact, 91.9% of patients in this study have CHA<sub>2</sub>DS<sub>2</sub>-VASc&#8201;&#8805;&#8201;2 and would have been recommended for OACs according to current guidelines [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The major limitation of CHA<sub>2</sub>DS<sub>2</sub>-VASc is the absence of cancer indicator, which has been suggested as an independent risk factor of stroke [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. A recently published study suggested the incorporation of cancer to CHA<sub>2</sub>DS<sub>2</sub>-VASc score to improve predictability of the original score [<xref ref-type="bibr" rid="CR52">52</xref>]. Indeed, CHA<sub>2</sub>DS<sub>2</sub>-VASc score is the linear combination of conditions in prediction of stroke [<xref ref-type="bibr" rid="CR10">10</xref>]. In the presence of cancer, the relationship between patient characteristics and ischemic stroke may become more complicated (i.e., non-linear), it is not surprising that CHA<sub>2</sub>DS<sub>2</sub>-VASc score failed to achieve high performance. In our study, linear models such as elastic net and SVM had lower performance metrics compared with non-linear models such as RF and XGBoost. Similar to CHA<sub>2</sub>DS<sub>2</sub>-VASc, we found prior stroke was among most important features in all ML algorithms. However, our approach incorporated a comprehensive set of patients&#8217; characteristics. For example, patients&#8217; socioeconomic status (household median income and education level) and cancer characteristics (cancer type, active cancer status) were ranked among top features in RF and XGBoost. The importance of these features highlighted contributions of health disparities and cancer characteristics in stroke prediction. The inclusion of these variables may be useful in identifying high-risk patients [<xref ref-type="bibr" rid="CR53">53</xref>]. However, it is also noticed that tree-based models may inflate the impact of continuous features in their prediction [<xref ref-type="bibr" rid="CR45">45</xref>]. Clinicians may consider initiating OACs for those who are at high risk of stroke identified by our RF algorithm.</p><p id="Par19">Traditional tools such as HAS-BLED or HEMORR<sub>2</sub>HAGES showed poor predictability in patients with cancer [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Our ML algorithms also failed to obtain high performance metrics in prediction of major bleeding. Such poor performance suggested complex interactions between patients&#8217; characteristics and outcomes in the presence of cancer. First, although we obtained additional cancer characteristics compared with traditional risk scores, the performance was not improved [<xref ref-type="bibr" rid="CR55">55</xref>]. This may suggest that our models failed to capture important features in prediction of major bleeding. In fact, genetic factors and disease severity were not available in SEER-Medicare data and dynamic features (i.e., cancer progression, new diagnosis of diseases) were not included in the models due to complexities. Similar to previous risk scores, we found that bleeding history was an important factor in prediction of subsequent major bleeding [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Second, we excluded patients who have already initiated OACs before AFib diagnosis and those who initiated AFib during follow-up because OACs may increase risk of bleeding. As a result, only 1.2% patients in our cohort experienced bleeding events during follow-up and this created a severe imbalance classification problem for our ML algorithms and may lead to poor predictability [<xref ref-type="bibr" rid="CR56">56</xref>]. Future studies may expand the outcomes to other types of bleeding (i.e., intracranial bleeding, gastrointestinal bleeding, or other non-critical site bleeding) to improve the performance and the clinical utility of the algorithms.</p><p id="Par20">In our study, SMOTE resampling approach did not improve the performance of the model. In the training set, SMOTE created new synthetic &#8216;stroke&#8217; individuals from interpolations of the original, real &#8216;stroke&#8217; cases [<xref ref-type="bibr" rid="CR48">48</xref>]. Studies have shown that SMOTE-like methods could improve the performance of weak classifiers such as SVM, decision tree [<xref ref-type="bibr" rid="CR57">57</xref>]. In our study, SMOTE improved AUCs in SVM only. Another limitation of SMOTE is that it resulted in poorly calibrated models where the probability of the minority class (stroke) was strongly inflated demonstrated by Brier score.</p><p id="Par21">Our study is subject to some limitations. We were unable to capture some important variables in the ML models (i.e., BMI, genetic factors, frailty, and health behaviors&#8212;not available in SEER-Medicare). Socioeconomic factors such as household income and education level are available on the aggregate area level (Census tract) but not individual level. In addition, our algorithms did not incorporate the impact of some post-baseline predictors (i.e., treatment dosage, adherence, recent CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores, recent use of NSAIDs, and other time-varying variables such as interactions between oral anticoagulants between OACs and antineoplastic agents) [<xref ref-type="bibr" rid="CR58">58</xref>]. Our study is applicable to the study period 2011&#8211;2019. From 2020, the presence Covid-19 has worsened outcomes of patients with AFib or cancer patients and has negatively impacted health services, delayed and reduced cancer screening and diagnosis in the United States [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>]. Therefore, the model should be updated and validated incorporating Covid-related factors during and after the pandemic. In addition, our ML algorithms could not further stratify the risk of stroke and major bleeding (i.e., low, moderate, high, or very high). Future study may leverage advanced ML algorithms such as survival ML in predicting the probability of adverse events after 1&#160;year or extended follow-up time. Last, the generalizability of our ML models to other populations may be limited (i.e., commercial insurance, anticoagulated patients, or patients with other cancer types).</p></sec><sec id="Sec17"><title>Conclusion</title><p id="Par22">Our study demonstrated a promising application of ML in stroke prediction among older adults with cancer who are newly diagnosed with AFib in the US. This tool may be leveraged in assisting clinicians in identification of patients at high risk of stroke and improving treatment decisions.</p></sec><sec sec-type="supplementary-material"><sec id="Sec18"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12012_2024_9843_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 6366 KB)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention&#8217;s (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute&#8217;s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors.</p></ack><notes notes-type="author-contribution"><title>Author Contribution</title><p>BT: Conceptualization; Data curation; Formal analysis; Methodology; Writing&#8212;original draft. BF: Methodology; Validation; Writing&#8212;review and editing. EC: Methodology; Validation; Writing&#8212;review and editing. JZ: Methodology; Validation; Writing&#8212;review and editing. LH: Methodology; Validation; Writing&#8212;review and editing. JQ: Conceptualization; Methodology; Supervision; Validation; Writing&#8212;review and editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par23">No conflicts of interest to report for all authors.</p></notes><notes id="FPar3"><title>Ethical Approval</title><p id="Par24">The study was granted exemption by the Auburn University institutional review board (IRB) and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>A</given-names></name><name name-style="western"><surname>Pant</surname><given-names>S</given-names></name><etal/></person-group><article-title>Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: Implications for healthcare planning</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>23</issue><fpage>2371</fpage><lpage>2379</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.008201</pub-id><pub-id pub-id-type="pmid">24842943</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Muntner</surname><given-names>P</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2019 update: A report from the American Heart Association</article-title><source>Circulation</source><year>2019</year><volume>139</volume><issue>10</issue><fpage>e56</fpage><lpage>e528</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000659</pub-id><pub-id pub-id-type="pmid">30700139</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention - National Center for Health Statistics. About Multiple Cause of Death, 1999&#8211;2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wonder.cdc.gov/mcd-icd10.html">https://wonder.cdc.gov/mcd-icd10.html</ext-link>. Published 2019. Retrieved October 14, 2021.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>MK</given-names></name><name name-style="western"><surname>Eckhardt</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Lifestyle and risk factor modification for reduction of atrial fibrillation: A Scientific statement from the American Heart Association</article-title><source>Circulation</source><year>2020</year><volume>141</volume><issue>16</issue><fpage>e750</fpage><lpage>e772</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000748</pub-id><pub-id pub-id-type="pmid">32148086</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timp</surname><given-names>JF</given-names></name><name name-style="western"><surname>Braekkan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>HH</given-names></name><name name-style="western"><surname>Cannegieter</surname><given-names>SC</given-names></name></person-group><article-title>Epidemiology of cancer-associated venous thrombosis</article-title><source>Blood</source><year>2013</year><volume>122</volume><issue>10</issue><fpage>1712</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-04-460121</pub-id><pub-id pub-id-type="pmid">23908465</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prandoni</surname><given-names>P</given-names></name><name name-style="western"><surname>Lensing</surname><given-names>AWA</given-names></name><name name-style="western"><surname>Piccioli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis</article-title><source>Blood</source><year>2002</year><volume>100</volume><issue>10</issue><fpage>3484</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-01-0108</pub-id><pub-id pub-id-type="pmid">12393647</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melloni</surname><given-names>C</given-names></name><name name-style="western"><surname>Shrader</surname><given-names>P</given-names></name><name name-style="western"><surname>Carver</surname><given-names>J</given-names></name><etal/></person-group><article-title>Management and outcomes of patients with atrial fibrillation and a history of cancer: The ORBIT-AF registry</article-title><source>European Heart Journal - Quality of Care and Clinical Outcomes</source><year>2017</year><volume>3</volume><issue>3</issue><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1093/ehjqcco/qcx004</pub-id><pub-id pub-id-type="pmid">28838088</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fanola</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ruff</surname><given-names>CT</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Efficacy and safety of Edoxaban in patients with active malignancy and atrial fibrillation: Analysis of the ENGAGE AF-TIMI 48 trial</article-title><source>Journal of the American Heart Association.</source><year>2018</year><volume>7</volume><issue>16</issue><fpage>e008987</fpage><pub-id pub-id-type="doi">10.1161/JAHA.118.008987</pub-id><pub-id pub-id-type="pmid">30369307</pub-id><pub-id pub-id-type="pmcid">PMC6201390</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorigue</surname><given-names>M</given-names></name><name name-style="western"><surname>Miljkovic</surname><given-names>MD</given-names></name></person-group><article-title>Atrial fibrillation and stroke risk in patients with cancer: A primer for oncologists</article-title><source>Journal of Oncology Practice.</source><year>2019</year><volume>15</volume><issue>12</issue><fpage>641</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1200/JOP.18.00592</pub-id><pub-id pub-id-type="pmid">31825754</pub-id><pub-id pub-id-type="pmcid">PMC7010430</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lip</surname><given-names>GY</given-names></name><name name-style="western"><surname>Nieuwlaat</surname><given-names>R</given-names></name><name name-style="western"><surname>Pisters</surname><given-names>R</given-names></name><name name-style="western"><surname>Lane</surname><given-names>DA</given-names></name><name name-style="western"><surname>Crijns</surname><given-names>HJ</given-names></name></person-group><article-title>Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation</article-title><source>Chest</source><year>2010</year><volume>137</volume><issue>2</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1378/chest.09-1584</pub-id><pub-id pub-id-type="pmid">19762550</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>January</surname><given-names>CT</given-names></name><name name-style="western"><surname>Wann</surname><given-names>LS</given-names></name><name name-style="western"><surname>Calkins</surname><given-names>H</given-names></name><etal/></person-group><article-title>2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons</article-title><source>Circulation</source><year>2019</year><volume>140</volume><issue>2</issue><fpage>e125</fpage><lpage>e151</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000665</pub-id><pub-id pub-id-type="pmid">30686041</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hindricks</surname><given-names>G</given-names></name><name name-style="western"><surname>Potpara</surname><given-names>T</given-names></name><name name-style="western"><surname>Dagres</surname><given-names>N</given-names></name><etal/></person-group><article-title>2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC</article-title><source>European Heart Journal.</source><year>2020</year><volume>42</volume><issue>5</issue><fpage>373</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa612</pub-id><pub-id pub-id-type="pmid">32860505</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Souza</surname><given-names>M</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>N</given-names></name><name name-style="western"><surname>Fosb&#248;l</surname><given-names>E</given-names></name><etal/></person-group><article-title>CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer</article-title><source>European Journal of Preventive Cardiology</source><year>2018</year><volume>25</volume><issue>6</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1177/2047487318759858</pub-id><pub-id pub-id-type="pmid">29482441</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patell</surname><given-names>R</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>A</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>L</given-names></name><name name-style="western"><surname>Khorana</surname><given-names>AA</given-names></name></person-group><article-title>Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation</article-title><source>American Journal of Cardiology</source><year>2017</year><volume>120</volume><issue>12</issue><fpage>2182</fpage><lpage>2186</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2017.08.038</pub-id><pub-id pub-id-type="pmid">29033049</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pisters</surname><given-names>R</given-names></name><name name-style="western"><surname>Lane</surname><given-names>DA</given-names></name><name name-style="western"><surname>Nieuwlaat</surname><given-names>R</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>CB</given-names></name><name name-style="western"><surname>Crijns</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey</article-title><source>Chest</source><year>2010</year><volume>138</volume><issue>5</issue><fpage>1093</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1378/chest.10-0134</pub-id><pub-id pub-id-type="pmid">20299623</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>JD</given-names></name><name name-style="western"><surname>Goodin</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lip</surname><given-names>GYH</given-names></name><name name-style="western"><surname>Adams</surname><given-names>VR</given-names></name></person-group><article-title>Risk stratification for bleeding complications in patients with venous thromboembolism: Application of the HAS-BLED bleeding score during the first 6&#160;months of anticoagulant treatment</article-title><source>Journal of the American Heart Association</source><year>2018</year><pub-id pub-id-type="doi">10.1161/JAHA.117.007901</pub-id><pub-id pub-id-type="pmid">29514808</pub-id><pub-id pub-id-type="pmcid">PMC5907554</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastori</surname><given-names>D</given-names></name><name name-style="western"><surname>Marang</surname><given-names>A</given-names></name><name name-style="western"><surname>Bisson</surname><given-names>A</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>J</given-names></name><name name-style="western"><surname>Lip</surname><given-names>GYH</given-names></name><name name-style="western"><surname>Fauchier</surname><given-names>L</given-names></name></person-group><article-title>Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer</article-title><source>European Heart Journal</source><year>2021</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehab724.0438</pub-id><pub-id pub-id-type="pmid">36444864</pub-id><pub-id pub-id-type="pmcid">PMC9851457</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chirikov</surname><given-names>VV</given-names></name><name name-style="western"><surname>Shaya</surname><given-names>FT</given-names></name><name name-style="western"><surname>Onukwugha</surname><given-names>E</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>CD</given-names></name><name name-style="western"><surname>dosReis</surname><given-names>S</given-names></name><name name-style="western"><surname>Howell</surname><given-names>CD</given-names></name></person-group><article-title>Tree-based claims algorithm for measuring pretreatment quality of care in medicare disabled hepatitis C patients</article-title><source>Medical Care</source><year>2017</year><volume>55</volume><issue>12</issue><fpage>e104</fpage><pub-id pub-id-type="doi">10.1097/MLR.0000000000000405</pub-id><pub-id pub-id-type="pmid">29135773</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>J</given-names></name><name name-style="western"><surname>Norman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hurst</surname><given-names>M</given-names></name><etal/></person-group><article-title>Using machine learning to predict anticoagulation control in atrial fibrillation: A UK clinical practice research datalink study</article-title><source>Informatics in Medicine Unlocked.</source><year>2021</year><volume>25</volume><fpage>100688</fpage><pub-id pub-id-type="doi">10.1016/j.imu.2021.100688</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spooner</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E</given-names></name><name name-style="western"><surname>Sowmya</surname><given-names>A</given-names></name><etal/></person-group><article-title>A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction</article-title><source>Scientific Reports.</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>20410</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-77220-w</pub-id><pub-id pub-id-type="pmid">33230128</pub-id><pub-id pub-id-type="pmcid">PMC7683682</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thottakkara</surname><given-names>P</given-names></name><name name-style="western"><surname>Ozrazgat-Baslanti</surname><given-names>T</given-names></name><name name-style="western"><surname>Hupf</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Application of machine learning techniques to high-dimensional clinical data to forecast postoperative complications</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>5</issue><fpage>e0155705</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0155705</pub-id><pub-id pub-id-type="pmid">27232332</pub-id><pub-id pub-id-type="pmcid">PMC4883761</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryo</surname><given-names>M</given-names></name><name name-style="western"><surname>Rillig</surname><given-names>MC</given-names></name></person-group><article-title>Statistically reinforced machine learning for nonlinear patterns and variable interactions</article-title><source>Ecosphere.</source><year>2017</year><volume>8</volume><issue>11</issue><fpage>e01976</fpage><pub-id pub-id-type="doi">10.1002/ecs2.1976</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>GS</given-names></name><name name-style="western"><surname>Reitsma</surname><given-names>JB</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Moons</surname><given-names>KGM</given-names></name></person-group><article-title>Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement</article-title><source>BMC Medicine.</source><year>2015</year><volume>13</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s12916-014-0241-z</pub-id><pub-id pub-id-type="pmid">25563062</pub-id><pub-id pub-id-type="pmcid">PMC4284921</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">National Cancer Institute. Overview of the Surveillance, Epidemiology, and End Results (SEER) Program. Retrieved December 27, 2021. from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/about/overview.html">https://seer.cancer.gov/about/overview.html</ext-link></mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>JL</given-names></name><name name-style="western"><surname>Klabunde</surname><given-names>CN</given-names></name><name name-style="western"><surname>Schrag</surname><given-names>D</given-names></name><name name-style="western"><surname>Bach</surname><given-names>PB</given-names></name><name name-style="western"><surname>Riley</surname><given-names>GF</given-names></name></person-group><article-title>Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population</article-title><source>Medical Care</source><year>2002</year><pub-id pub-id-type="doi">10.1097/00005650-200208001-00002</pub-id><pub-id pub-id-type="pmid">12187163</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>PN</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>J</given-names></name><name name-style="western"><surname>Heckbert</surname><given-names>SR</given-names></name><name name-style="western"><surname>Carnahan</surname><given-names>R</given-names></name><name name-style="western"><surname>Dublin</surname><given-names>S</given-names></name></person-group><article-title>A systematic review of validated methods for identifying atrial fibrillation using administrative data</article-title><source>Pharmacoepidemiology and Drug Safety</source><year>2012</year><pub-id pub-id-type="doi">10.1002/pds.2317</pub-id><pub-id pub-id-type="pmid">22262600</pub-id><pub-id pub-id-type="pmcid">PMC3674852</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyman</surname><given-names>GH</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>M</given-names></name><name name-style="western"><surname>Ay</surname><given-names>C</given-names></name><etal/></person-group><article-title>American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer</article-title><source>Blood Advances.</source><year>2021</year><volume>5</volume><issue>4</issue><fpage>927</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003442</pub-id><pub-id pub-id-type="pmid">33570602</pub-id><pub-id pub-id-type="pmcid">PMC7903232</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>CM</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bonow</surname><given-names>RO</given-names></name><etal/></person-group><article-title>2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines</article-title><source>Circulation</source><year>2021</year><volume>143</volume><issue>5</issue><fpage>e72</fpage><lpage>e227</lpage><pub-id pub-id-type="pmid">33332150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000923</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deitelzweig</surname><given-names>S</given-names></name><name name-style="western"><surname>Keshishian</surname><given-names>AV</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effectiveness and Safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer</article-title><source>JACC: CardioOncology.</source><year>2021</year><volume>3</volume><issue>3</issue><fpage>411</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">34604802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaccao.2021.06.004</pub-id><pub-id pub-id-type="pmcid">PMC8463723</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thigpen</surname><given-names>JL</given-names></name><name name-style="western"><surname>Dillon</surname><given-names>C</given-names></name><name name-style="western"><surname>Forster</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation</article-title><source>Circulation Cardiovascular Quality and Outcomes</source><year>2015</year><volume>8</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.113.000371</pub-id><pub-id pub-id-type="pmid">25587093</pub-id><pub-id pub-id-type="pmcid">PMC4654947</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>A</given-names></name><name name-style="western"><surname>Stein</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chung</surname><given-names>CP</given-names></name><name name-style="western"><surname>Daugherty</surname><given-names>JR</given-names></name><name name-style="western"><surname>Smalley</surname><given-names>WE</given-names></name><name name-style="western"><surname>Ray</surname><given-names>WA</given-names></name></person-group><article-title>An automated database case definition for serious bleeding related to oral anticoagulant use</article-title><source>Pharmacoepidemiology and drug safety.</source><year>2011</year><volume>20</volume><issue>6</issue><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1002/pds.2109</pub-id><pub-id pub-id-type="pmid">21387461</pub-id><pub-id pub-id-type="pmcid">PMC3365595</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S</given-names></name><name name-style="western"><surname>Norby</surname><given-names>FL</given-names></name><name name-style="western"><surname>Datta</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation</article-title><source>Blood Advances</source><year>2018</year><volume>2</volume><issue>3</issue><fpage>200</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2017010694</pub-id><pub-id pub-id-type="pmid">29378726</pub-id><pub-id pub-id-type="pmcid">PMC5812321</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Ezekowitz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dabigatran versus Warfarin in patients with atrial fibrillation</article-title><source>New England Journal of Medicine.</source><year>2009</year><volume>361</volume><issue>12</issue><fpage>1139</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0905561</pub-id><pub-id pub-id-type="pmid">19717844</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waljee</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>A</given-names></name><name name-style="western"><surname>Singal</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Comparison of imputation methods for missing laboratory data in medicine</article-title><source>British Medical Journal Open</source><year>2013</year><volume>3</volume><issue>8</issue><fpage>e002847</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2013-002847</pub-id><pub-id pub-id-type="pmcid">PMC3733317</pub-id><pub-id pub-id-type="pmid">23906948</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stekhoven</surname><given-names>DJ</given-names></name><name name-style="western"><surname>B&#252;hlmann</surname><given-names>P</given-names></name></person-group><article-title>MissForest&#8212;non-parametric missing value imputation for mixed-type data</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><issue>1</issue><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr597</pub-id><pub-id pub-id-type="pmid">22039212</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goodacre</surname><given-names>R</given-names></name></person-group><article-title>On splitting training and validation set: A comparative study of cross-validation, bootstrap and systematic sampling for estimating the generalization performance of supervised learning</article-title><source>Journal of Analysis and Testing.</source><year>2018</year><volume>2</volume><issue>3</issue><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s41664-018-0068-2</pub-id><pub-id pub-id-type="pmid">30842888</pub-id><pub-id pub-id-type="pmcid">PMC6373628</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Cocea</surname><given-names>M</given-names></name></person-group><article-title>Semi-random partitioning of data into training and test sets in granular computing context</article-title><source>Granular Computing.</source><year>2017</year><volume>2</volume><issue>4</issue><fpage>357</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1007/s41066-017-0049-2</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cawley</surname><given-names>GC</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>NLC</given-names></name></person-group><article-title>On over-fitting in model selection and subsequent selection bias in performance evaluation</article-title><source>Journal of Machine Learning Research</source><year>2010</year><volume>11</volume><fpage>2079</fpage><lpage>2107</lpage></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claxton</surname><given-names>JS</given-names></name><name name-style="western"><surname>MacLehose</surname><given-names>RF</given-names></name><name name-style="western"><surname>Lutsey</surname><given-names>PL</given-names></name><etal/></person-group><article-title>A new model to predict ischemic stroke in patients with atrial fibrillation using warfarin or direct oral anticoagulants</article-title><source>Heart Rhythm</source><year>2019</year><volume>16</volume><issue>6</issue><fpage>820</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2018.12.005</pub-id><pub-id pub-id-type="pmid">30550837</pub-id><pub-id pub-id-type="pmcid">PMC6545238</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Brownlee, J. (2020). <italic toggle="yes">Imbalanced Classification with Python: Better Metrics, Balance Skewed Classes, Cost-Sensitive Learning.</italic> Machine Learning Mastery.</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Goorbergh</surname><given-names>R</given-names></name><name name-style="western"><surname>van Smeden</surname><given-names>M</given-names></name><name name-style="western"><surname>Timmerman</surname><given-names>D</given-names></name><name name-style="western"><surname>Van Calster</surname><given-names>B</given-names></name></person-group><article-title>The harm of class imbalance corrections for risk prediction models: Illustration and simulation using logistic regression</article-title><source>Journal of the American Medical Informatics Association</source><year>2022</year><volume>29</volume><issue>9</issue><fpage>1525</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1093/jamia/ocac093</pub-id><pub-id pub-id-type="pmid">35686364</pub-id><pub-id pub-id-type="pmcid">PMC9382395</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeLong</surname><given-names>ER</given-names></name><name name-style="western"><surname>DeLong</surname><given-names>DM</given-names></name><name name-style="western"><surname>Clarke-Pearson</surname><given-names>DL</given-names></name></person-group><article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach</article-title><source>Biometrics</source><year>1988</year><volume>44</volume><issue>3</issue><fpage>837</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.2307/2531595</pub-id><pub-id pub-id-type="pmid">3203132</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devarriya</surname><given-names>D</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>C</given-names></name><name name-style="western"><surname>Mansharamani</surname><given-names>V</given-names></name><name name-style="western"><surname>Sakalle</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>A</given-names></name></person-group><article-title>Unbalanced breast cancer data classification using novel fitness functions in genetic programming</article-title><source>Expert Systems with Applications.</source><year>2020</year><volume>140</volume><fpage>112866</fpage><pub-id pub-id-type="doi">10.1016/j.eswa.2019.112866</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saarela</surname><given-names>M</given-names></name><name name-style="western"><surname>Jauhiainen</surname><given-names>S</given-names></name></person-group><article-title>Comparison of feature importance measures as explanations for classification models</article-title><source>SN Applied Sciences.</source><year>2021</year><volume>3</volume><issue>2</issue><fpage>272</fpage><pub-id pub-id-type="doi">10.1007/s42452-021-04148-9</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strobl</surname><given-names>C</given-names></name><name name-style="western"><surname>Boulesteix</surname><given-names>A-L</given-names></name><name name-style="western"><surname>Zeileis</surname><given-names>A</given-names></name><name name-style="western"><surname>Hothorn</surname><given-names>T</given-names></name></person-group><article-title>Bias in random forest variable importance measures: Illustrations, sources and a solution</article-title><source>BMC Bioinformatics</source><year>2007</year><volume>8</volume><issue>1</issue><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-8-25</pub-id><pub-id pub-id-type="pmid">17254353</pub-id><pub-id pub-id-type="pmcid">PMC1796903</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loecher</surname><given-names>M</given-names></name></person-group><article-title>Unbiased variable importance for random forests</article-title><source>Communications in Statistics - Theory and Methods.</source><year>2022</year><volume>51</volume><issue>5</issue><fpage>1413</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1080/03610926.2020.1764042</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Macheret</surname><given-names>F</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>RA</given-names></name><name name-style="western"><surname>Ohno-Machado</surname><given-names>L</given-names></name></person-group><article-title>A tutorial on calibration measurements and calibration models for clinical prediction models</article-title><source>Journal of the American Medical Informatics Association.</source><year>2020</year><volume>27</volume><issue>4</issue><fpage>621</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1093/jamia/ocz228</pub-id><pub-id pub-id-type="pmid">32106284</pub-id><pub-id pub-id-type="pmcid">PMC7075534</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chawla</surname><given-names>N</given-names></name><name name-style="western"><surname>Bowyer</surname><given-names>K</given-names></name><name name-style="western"><surname>Hall</surname><given-names>L</given-names></name><name name-style="western"><surname>Kegelmeyer</surname><given-names>W</given-names></name></person-group><article-title>SMOTE: Synthetic minority over-sampling technique</article-title><source>J Artif Intell Res (JAIR).</source><year>2002</year><volume>16</volume><fpage>321</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1613/jair.953</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Souza</surname><given-names>M</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>N</given-names></name><name name-style="western"><surname>Fosb&#248;l</surname><given-names>E</given-names></name><etal/></person-group><article-title>CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer</article-title><source>European Journal of Preventive Cardiology.</source><year>2018</year><volume>25</volume><issue>6</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1177/2047487318759858</pub-id><pub-id pub-id-type="pmid">29482441</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navi</surname><given-names>BB</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between incident cancer and subsequent stroke</article-title><source>Annals of Neurology</source><year>2015</year><volume>77</volume><issue>2</issue><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1002/ana.24325</pub-id><pub-id pub-id-type="pmid">25472885</pub-id><pub-id pub-id-type="pmcid">PMC4315703</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>OY</given-names></name><name name-style="western"><surname>Chung</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Seo</surname><given-names>WK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GM</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer-related stroke: An emerging subtype of ischemic stroke with unique pathomechanisms</article-title><source>J Stroke.</source><year>2020</year><volume>22</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.5853/jos.2019.02278</pub-id><pub-id pub-id-type="pmid">32027788</pub-id><pub-id pub-id-type="pmcid">PMC7005348</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bungo</surname><given-names>B</given-names></name><name name-style="western"><surname>Chaudhury</surname><given-names>P</given-names></name><name name-style="western"><surname>Arustamyan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score</article-title><source>IJC Heart &amp; Vasculature.</source><year>2022</year><volume>41</volume><fpage>101072</fpage><pub-id pub-id-type="doi">10.1016/j.ijcha.2022.101072</pub-id><pub-id pub-id-type="pmid">35757148</pub-id><pub-id pub-id-type="pmcid">PMC9218829</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindmark</surname><given-names>A</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></name><name name-style="western"><surname>Darehed</surname><given-names>D</given-names></name></person-group><article-title>Socioeconomic status and stroke severity: Understanding indirect effects via risk factors and stroke prevention using innovative statistical methods for mediation analysis</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>6</issue><fpage>e0270533</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0270533</pub-id><pub-id pub-id-type="pmid">35749530</pub-id><pub-id pub-id-type="pmcid">PMC9232158</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raposeiras Roub&#237;n</surname><given-names>S</given-names></name><name name-style="western"><surname>Abu Assi</surname><given-names>E</given-names></name><name name-style="western"><surname>Mu&#241;oz Pousa</surname><given-names>I</given-names></name><etal/></person-group><article-title>Incidence and predictors of bleeding in patients with cancer and atrial fibrillation</article-title><source>American Journal of Cardiology</source><year>2022</year><volume>167</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2021.11.053</pub-id><pub-id pub-id-type="pmid">35027138</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trinks-Roerdink</surname><given-names>EM</given-names></name><name name-style="western"><surname>Geersing</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Hemels</surname><given-names>MEW</given-names></name><etal/></person-group><article-title>External validation and updating of prediction models of bleeding risk in patients with cancer receiving anticoagulants</article-title><source>Open Heart.</source><year>2023</year><volume>10</volume><issue>1</issue><fpage>e002273</fpage><pub-id pub-id-type="doi">10.1136/openhrt-2023-002273</pub-id><pub-id pub-id-type="pmid">37055175</pub-id><pub-id pub-id-type="pmcid">PMC10106080</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>J</given-names></name></person-group><article-title>Research on expansion and classification of imbalanced data based on SMOTE algorithm</article-title><source>Scientific Reports.</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>24039</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-03430-5</pub-id><pub-id pub-id-type="pmid">34912009</pub-id><pub-id pub-id-type="pmcid">PMC8674253</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Elor Y, Averbuch-Elor H. To SMOTE, or not to SMOTE? <italic toggle="yes">arXiv preprint arXiv:220108528.</italic> 2022.</mixed-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truong</surname><given-names>B</given-names></name><name name-style="western"><surname>Hornsby</surname><given-names>L</given-names></name><name name-style="western"><surname>Fox</surname><given-names>BI</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name></person-group><article-title>Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: A pharmacovigilance approach</article-title><source>Journal of Thrombosis and Thrombolysis.</source><year>2023</year><volume>56</volume><issue>4</issue><fpage>555</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1007/s11239-023-02879-7</pub-id><pub-id pub-id-type="pmid">37563503</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>LY</given-names></name><name name-style="western"><surname>Cazier</surname><given-names>JB</given-names></name><name name-style="western"><surname>Angelis</surname><given-names>V</given-names></name><etal/></person-group><article-title>COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10241</issue><fpage>1919</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31173-9</pub-id><pub-id pub-id-type="pmid">32473682</pub-id><pub-id pub-id-type="pmcid">PMC7255715</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardo Sanz</surname><given-names>A</given-names></name><name name-style="western"><surname>Salido Tahoces</surname><given-names>L</given-names></name><name name-style="western"><surname>Ortega P&#233;rez</surname><given-names>R</given-names></name><name name-style="western"><surname>Gonz&#225;lez Ferrer</surname><given-names>E</given-names></name><name name-style="western"><surname>S&#225;nchez Recalde</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Zamorano G&#243;mez</surname><given-names>JL</given-names></name></person-group><article-title>New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis</article-title><source>Cardiology Journal</source><year>2021</year><volume>28</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.5603/CJ.a2020.0145</pub-id><pub-id pub-id-type="pmid">33140386</pub-id><pub-id pub-id-type="pmcid">PMC8105065</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenblatt</surname><given-names>AG</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>CR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A</given-names></name><etal/></person-group><article-title>New-onset atrial fibrillation in patients hospitalized with COVID-19: Results from the american heart association COVID-19 cardiovascular registry</article-title><source>Circulation: Arrhythmia and Electrophysiology.</source><year>2022</year><volume>15</volume><issue>5</issue><fpage>e010666</fpage><pub-id pub-id-type="pmid">35475654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCEP.121.010666</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariotto</surname><given-names>AB</given-names></name><name name-style="western"><surname>Feuer</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Howlader</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-S</given-names></name><name name-style="western"><surname>Negoita</surname><given-names>S</given-names></name><name name-style="western"><surname>Cronin</surname><given-names>KA</given-names></name></person-group><article-title>Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic</article-title><source>JNCI: Journal of the National Cancer Institute.</source><year>2023</year><volume>115</volume><issue>9</issue><fpage>1109</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1093/jnci/djad086</pub-id><pub-id pub-id-type="pmid">37220901</pub-id><pub-id pub-id-type="pmcid">PMC10483261</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">National Cancer Institute. Impact of COVID on 2020 SEER Cancer Incidence Data. Retrieved February 12, 2024 from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/data/covid-impact.html">https://seer.cancer.gov/data/covid-impact.html</ext-link></mixed-citation></ref></ref-list></back></article></pmc-articleset>